ERBB2 and non-small cell lung carcinoma: Also, a phase II trial (ELPIS) is ongoing to evaluate the efficacy and safety of T-DXd in HER2 MUT NSCLC with asymptomatic brain metastases, with the primary endpoint being intracranial-progression-free-survival (IC-PFS), as defined by Response Assessment in Neuro-Oncology (RANO) criteria (NCT06250777).